600267 海正药业
已收盘 10-16 15:00:00
资讯
新帖
简况
海正药业（600267）披露2026年前三季度经营数据，10月16日股价下跌1.88%
证券之星 · 10-16 22:33
海正药业（600267）披露2026年前三季度经营数据，10月16日股价下跌1.88%
海正药业：预计2026年1-9月归属净利润盈利约11.5亿元
证券之星 · 10-16 18:01
海正药业：预计2026年1-9月归属净利润盈利约11.5亿元
海正药业（600267）披露完成工商变更登记并换发营业执照公告，10月13日股价下跌1.62%
证券之星 · 10-13
海正药业（600267）披露完成工商变更登记并换发营业执照公告，10月13日股价下跌1.62%
股市必读：海正药业新发布《浙江海正药业股份有限公司关于子公司获得兽药产品批准文号批件的公告》
证券之星 · 10-12
股市必读：海正药业新发布《浙江海正药业股份有限公司关于子公司获得兽药产品批准文号批件的公告》
海正药业（600267）披露子公司获得兽药产品批准文号批件，10月9日股价上涨2.58%
证券之星 · 10-09
海正药业（600267）披露子公司获得兽药产品批准文号批件，10月9日股价上涨2.58%
股市必读：海正药业新发布《简式权益变动报告书（金浦浙展）》
证券之星 · 09-29
股市必读：海正药业新发布《简式权益变动报告书（金浦浙展）》
海正药业（600267）披露持股5%以上股东协议转让股份提示性公告，9月28日股价上涨0.96%
证券之星 · 09-28
海正药业（600267）披露持股5%以上股东协议转让股份提示性公告，9月28日股价上涨0.96%
股市必读：海正药业新发布《简式权益变动报告书（金浦浙展）》
证券之星 · 09-28
股市必读：海正药业新发布《简式权益变动报告书（金浦浙展）》
海正药业最新公告：子公司获复方非泼罗尼吡喹酮莫昔克丁滴剂兽药批准文号
证券之星 · 09-14
海正药业最新公告：子公司获复方非泼罗尼吡喹酮莫昔克丁滴剂兽药批准文号
海正药业出席 BIOHK2026：转型生物制造，布局大健康
新浪财经 · 09-14
海正药业出席 BIOHK2026：转型生物制造，布局大健康
股市必读：海正药业新发布《北京康达（杭州）律师事务所关于浙江海正药业股份有限公司2026年第三次临时股东会的法律意见书》
证券之星 · 09-14
股市必读：海正药业新发布《北京康达（杭州）律师事务所关于浙江海正药业股份有限公司2026年第三次临时股东会的法律意见书》
每周股票复盘：海正药业（600267）子公司获新兽药注册证书
证券之星 · 09-13
每周股票复盘：海正药业（600267）子公司获新兽药注册证书
海正药业(600267.SH)子公司盐酸氨基葡萄糖通过美国Self-GRAS认证
智通财经 · 09-11
海正药业(600267.SH)子公司盐酸氨基葡萄糖通过美国Self-GRAS认证
海正药业获得发明专利授权：“三环类衍生物及其制备方法和用途”
证券之星 · 09-11
海正药业获得发明专利授权：“三环类衍生物及其制备方法和用途”
海正药业（600267）披露修订《公司章程》部分条款议案获通过，9月10日股价下跌1.72%
证券之星 · 09-10
海正药业（600267）披露修订《公司章程》部分条款议案获通过，9月10日股价下跌1.72%
海正药业（600267）披露子公司获得新兽药注册证书公告，9月8日股价上涨1.12%
证券之星 · 09-08
海正药业（600267）披露子公司获得新兽药注册证书公告，9月8日股价上涨1.12%
每周股票复盘：海正药业（600267）拟修订章程增高级副总裁职数
证券之星 · 09-06
每周股票复盘：海正药业（600267）拟修订章程增高级副总裁职数
股市必读：海正药业新发布《浙江海正药业股份有限公司2026年第三次临时股东会资料》
证券之星 · 09-04
股市必读：海正药业新发布《浙江海正药业股份有限公司2026年第三次临时股东会资料》
每周股票复盘：海正药业（600267）Q2净利增167.81%
证券之星 · 08-30
每周股票复盘：海正药业（600267）Q2净利增167.81%
图解海正药业中报：第二季度单季净利润同比增长167.81%
证券之星 · 08-26
图解海正药业中报：第二季度单季净利润同比增长167.81%
公司概况
公司名称：
浙江海正药业股份有限公司
所属行业：
医药制造业
上市日期：
2000-07-25
主营业务：
浙江海正药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是海博麦布片（赛斯美）、注射用哌拉西林钠他唑巴坦钠（特治星）、盐酸米诺环素胶囊（玫满）、茚达特罗格隆溴铵吸入粉雾剂（杰润）、注射用丝裂霉素、瑞舒伐他汀钙片（海舒严）、注射用亚胺培南西司他丁钠（俊特）、米尔贝肟吡喹酮片（海乐妙）、丁二磺酸腺苷蛋氨酸肠溶片（喜美欣）、英夫马芬净。
发行价格：
11.83
{"stockData":{"symbol":"600267","market":"SH","secType":"STK","nameCN":"海正药业","latestPrice":10.96,"timestamp":1792134000000,"preClose":11.17,"halted":0,"volume":27897754,"delay":0,"changeRate":-0.0188,"floatShares":1180000000,"shares":1180000000,"eps":0.744,"marketStatus":"已收盘","change":-0.21,"latestTime":"10-16 15:00:00","open":11.24,"high":11.5,"low":10.84,"amount":313000000,"amplitude":0.0591,"askPrice":10.96,"askSize":43,"bidPrice":10.95,"bidSize":1573,"shortable":0,"etf":0,"ttmEps":0.744,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792373400000},"marketStatusCode":5,"adr":0,"adjPreClose":11.17,"symbolType":"stock","openAndCloseTimeList":[[1792114200000,1792121400000],[1792126800000,1792134000000]],"highLimit":12.29,"lowLimit":10.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1180272096,"isCdr":false,"pbRate":1.44,"roa":"--","peRate":14.731183,"roe":"7.2%","epsLYR":0.46,"committee":0.455887,"marketValue":12936000000,"turnoverRate":0.0236,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-20。","floatMarketCap":12936000000},"requestUrl":"/m/hq/s/600267/wiki","defaultTab":"wiki","newsList":[{"id":"2675518361","title":"海正药业（600267）披露2026年前三季度经营数据，10月16日股价下跌1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675518361","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675518361?lang=zh_cn&edition=full","pubTime":"2026-10-16 22:33","pubTimestamp":1792161205,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘，海正药业报收于10.96元，较前一交易日下跌1.88%，最新总市值为129.36亿元。该股当日开盘11.24元，最高11.5元，最低10.84元，成交额达3.13亿元，换手率为2.36%。近日，浙江海正药业股份有限公司发布《关于2026年前三季度经营数据的公告》。公告显示，公司预计2026年前三季度实现营业收入65.2亿元左右，同比下降17.71%；归属于上市公司股东的净利润11.5亿元左右，同比增长149.46%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600040490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0028","600267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675593258","title":"海正药业：预计2026年1-9月归属净利润盈利约11.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675593258","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675593258?lang=zh_cn&edition=full","pubTime":"2026-10-16 18:01","pubTimestamp":1792144864,"startTime":"0","endTime":"0","summary":"证券之星消息，海正药业发布业绩预告，预计2026年1-9月归属净利润盈利约11.5亿元。海正药业2026年中报显示，上半年度公司主营收入44.75亿元，同比下降14.76%；归母净利润6.36亿元，同比上升112.82%；扣非净利润5.13亿元，同比上升59.78%；其中2026年第二季度，公司单季度主营收入20.85亿元，同比下降20.37%；单季度归母净利润2.81亿元，同比上升167.81%；单季度扣非净利润2.77亿元，同比上升99.55%；负债率31.84%，投资收益1.76亿元，财务费用3133.85万元，毛利率55.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600031208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675368525","title":"海正药业（600267）披露完成工商变更登记并换发营业执照公告，10月13日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675368525","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675368525?lang=zh_cn&edition=full","pubTime":"2026-10-13 22:26","pubTimestamp":1791901580,"startTime":"0","endTime":"0","summary":"近日，浙江海正药业股份有限公司发布《关于完成工商变更登记并换发营业执照的公告》。公告显示，公司于2026年4月3日召开第十届董事会第十四次会议，并于2026年4月28日召开2025年年度股东会，审议通过了关于变更注册资本、修订《公司章程》及办理工商变更登记的议案。近日，公司已完成相关工商变更登记及修订后《公司章程》的备案手续，并取得浙江省市场监督管理局换发的《营业执照》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300040014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","600267","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674845682","title":"股市必读：海正药业新发布《浙江海正药业股份有限公司关于子公司获得兽药产品批准文号批件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674845682","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674845682?lang=zh_cn&edition=full","pubTime":"2026-10-12 02:06","pubTimestamp":1791741977,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司获替米沙坦内服溶液（猫用）兽药产品批准文号，有效期至2031年10月7日，已具备上市销售条件。公司公告汇总浙江海正药业股份有限公司关于子公司获得兽药产品批准文号批件的公告浙江海正药业股份有限公司控股子公司浙江海正动物保健品有限公司收到农业农村部核准签发的替米沙坦内服溶液（猫用）兽药产品批准文号批件，批准文号为兽药字110803434，有效期至2031年10月7日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600267","BK0239","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674850675","title":"海正药业（600267）披露子公司获得兽药产品批准文号批件，10月9日股价上涨2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674850675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674850675?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:22","pubTimestamp":1791555740,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，海正药业报收于11.94元，较前一交易日上涨2.58%，最新总市值为140.92亿元。近日，浙江海正药业股份有限公司发布《关于子公司获得兽药产品批准文号批件的公告》。公告显示，公司控股子公司浙江海正动物保健品有限公司收到农业农村部核准签发的替米沙坦内服溶液（猫用）兽药产品批准文号批件，批准文号为兽药字110803434，有效期至2031年10月7日。该产品用于治疗猫慢性肾病引起的蛋白尿，已具备上市销售条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900038398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0060","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671254728","title":"股市必读：海正药业新发布《简式权益变动报告书（金浦浙展）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671254728","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671254728?lang=zh_cn&edition=full","pubTime":"2026-09-29 02:08","pubTimestamp":1790618895,"startTime":"0","endTime":"0","summary":"本次权益变动后，金浦浙展持有上市公司6.16%股份，资金来源为其合伙人实缴出资。转让后公司第一大股东不变，不导致控制权变更。简式权益变动报告书浙江省国际贸易集团有限公司拟通过公开征集协议转让方式，将其持有的浙江海正药业股份有限公司72,673,907股无限售A股流通股转让给金浦浙展股权投资（丽水）合伙企业。本次权益变动尚需履行国有股权管理信息系统备案、上交所合规性确认及中登公司过户登记等程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900001990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0239","BK0028","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670060235","title":"海正药业（600267）披露持股5%以上股东协议转让股份提示性公告，9月28日股价上涨0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670060235","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670060235?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:56","pubTimestamp":1790589370,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，海正药业报收于11.54元，较前一交易日上涨0.96%，最新总市值为136.2亿元。近日，浙江海正药业股份有限公司发布《关于持股5%以上股东通过公开征集转让方式协议转让公司股份的结果暨与受让方签订〈股份转让协议〉的提示性公告》。本次转让需履行国有股权管理信息系统备案、上交所合规性确认及股份过户登记等程序，尚未完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800023828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0239","BK0028","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409867","title":"股市必读：海正药业新发布《简式权益变动报告书（金浦浙展）》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409867?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:13","pubTimestamp":1790529188,"startTime":"0","endTime":"0","summary":"本次权益变动后，金浦浙展持有上市公司6.16%股份，资金来源为其合伙人实缴出资。转让后公司第一大股东不变，不导致控制权变更。简式权益变动报告书浙江省国际贸易集团有限公司拟通过公开征集协议转让方式，将其持有的浙江海正药业股份有限公司72,673,907股无限售A股流通股转让给金浦浙展股权投资（丽水）合伙企业。本次权益变动尚需履行国有股权管理信息系统备案、上交所合规性确认及中登公司过户登记等程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600267","BK0239","BK0028","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654179","title":"海正药业最新公告：子公司获复方非泼罗尼吡喹酮莫昔克丁滴剂兽药批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654179","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654179?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:28","pubTimestamp":1789378082,"startTime":"0","endTime":"0","summary":"海正药业(600267.SH)公告称，公司控股子公司海正动保公司收到农业农村部核准签发的复方非泼罗尼吡喹酮莫昔克丁滴剂兽药产品批准文号批件。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400022573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0239","BK0188","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667634668","title":"海正药业出席 BIOHK2026：转型生物制造，布局大健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2667634668","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667634668?lang=zh_cn&edition=full","pubTime":"2026-09-14 10:48","pubTimestamp":1789354080,"startTime":"0","endTime":"0","summary":"2026年9月9日-12日，第五届香港国际生物科技论坛暨展览在香港会议展览中心举行。浙江海正药业股份有限公司董事长、总裁肖卫红受邀出席主论坛并发表主旨演讲，正式宣告公司从传统化学制药向生物制造转型，并布局包括运动健康在内的大健康领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tob/2026-09-14/doc-iniruhxh4729507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600267","BK0188","BK0060","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680419","title":"股市必读：海正药业新发布《北京康达（杭州）律师事务所关于浙江海正药业股份有限公司2026年第三次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680419","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680419?lang=zh_cn&edition=full","pubTime":"2026-09-14 02:15","pubTimestamp":1789323311,"startTime":"0","endTime":"0","summary":"浙江海正药业股份有限公司2026年第三次临时股东会决议公告浙江海正药业股份有限公司于2026年9月10日召开2026年第三次临时股东会，会议由董事会召集，董事杜加秋主持，采用现场与网络投票相结合方式召开。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0028","BK0188","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507236","title":"每周股票复盘：海正药业（600267）子公司获新兽药注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507236","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507236?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:33","pubTimestamp":1789237990,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，海正药业报收于11.13元，较上周的11.64元下跌4.38%。本周关注点公司公告汇总：子公司获复方非泼罗尼吡喹酮莫昔克丁滴剂新兽药注册证书。浙江海正药业股份有限公司于2026年9月10日召开2026年第三次临时股东会，会议由董事会召集，董事杜加秋主持，采用现场与网络投票相结合方式召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600267","BK0060","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666523008","title":"海正药业(600267.SH)子公司盐酸氨基葡萄糖通过美国Self-GRAS认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2666523008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666523008?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:01","pubTimestamp":1789120917,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海正药业 发布公告，近日，公司全资子公司浙江沄生合成生物科技有限公司产品盐酸氨基葡萄糖，按照美国FDA GRAS准则完成Self-GRAS科学评价并获得专家组一致批准，正式通过美国Self-GRAS认证。据悉，盐酸氨基葡萄糖是高价值食品级原料，在食品配方与营养配料领域应用广泛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海正药业(600267.SH)子公司盐酸氨基葡萄糖通过美国Self-GRAS认证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0188","600267","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518429","title":"海正药业获得发明专利授权：“三环类衍生物及其制备方法和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666518429?lang=zh_cn&edition=full","pubTime":"2026-09-11 03:27","pubTimestamp":1789068462,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示海正药业新获得一项发明专利授权，专利名为“三环类衍生物及其制备方法和用途”，专利申请号为CN202110323822.3，授权日为2026年8月28日。今年以来海正药业新获得专利授权7个，较去年同期减少了41.67%。通过天眼查大数据分析，浙江海正药业股份有限公司共对外投资了27家企业，参与招投标项目5344次；财产线索方面有商标信息273条，专利信息519条，著作权信息1条；此外企业还拥有行政许可559个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100004864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0060","BK0239","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666916865","title":"海正药业（600267）披露修订《公司章程》部分条款议案获通过，9月10日股价下跌1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666916865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666916865?lang=zh_cn&edition=full","pubTime":"2026-09-10 22:15","pubTimestamp":1789049717,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，海正药业报收于11.41元，较前一交易日下跌1.72%，最新总市值为134.67亿元。该股当日开盘11.57元，最高11.59元，最低11.25元，成交额达2.4亿元，换手率为1.79%。公告显示，公司于2026年9月10日召开2026年第三次临时股东会，审议通过了《关于修订〈公司章程〉部分条款的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000041977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600267","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665292983","title":"海正药业（600267）披露子公司获得新兽药注册证书公告，9月8日股价上涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665292983","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665292983?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:58","pubTimestamp":1788861490,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，海正药业报收于11.74元，较前一交易日上涨1.12%，最新总市值为138.56亿元。该股当日开盘11.62元，最高11.77元，最低11.52元，成交额达2.44亿元，换手率为1.78%。该产品已具备生产和上市条件，待取得兽药产品批准文号后可上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0060","600267","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365452","title":"每周股票复盘：海正药业（600267）拟修订章程增高级副总裁职数","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365452","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365452?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:11","pubTimestamp":1788631869,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，海正药业报收于11.64元，较上周的12.2元下跌4.59%。公司公告汇总：2026年第三次临时股东会将于9月10日召开，审议修订公司章程议案。公司公告汇总浙江海正药业股份有限公司拟修订《公司章程》部分条款，将公司高级副总裁职数由1至4名调整为1至5名。浙江海正药业股份有限公司将于2026年9月10日召开2026年第三次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267","BK0028","BK0188","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664805200","title":"股市必读：海正药业新发布《浙江海正药业股份有限公司2026年第三次临时股东会资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664805200","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664805200?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:25","pubTimestamp":1788456312,"startTime":"0","endTime":"0","summary":"公司公告汇总浙江海正药业股份有限公司2026年第三次临时股东会资料浙江海正药业股份有限公司拟修订《公司章程》部分条款，将公司高级副总裁职数由1至4名调整为1至5名。浙江海正药业股份有限公司关于召开2026年第三次临时股东会的提示性公告浙江海正药业股份有限公司将于2026年9月10日召开2026年第三次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400001975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0060","600267"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048853","title":"每周股票复盘：海正药业（600267）Q2净利增167.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048853","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048853?lang=zh_cn&edition=full","pubTime":"2026-08-30 05:00","pubTimestamp":1788037240,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，海正药业报收于12.2元，较上周的13.08元下跌6.73%。本周，海正药业8月24日盘中最高价报13.09元。股本股东变化截至2026年6月30日，海正药业股东户数为4.88万户，较3月31日增加1153户，增幅2.42%。第二季度单季营收20.85亿元，同比下降20.37%；单季归母净利润2.81亿元，同比上升167.81%；单季扣非净利润2.77亿元，同比上升99.55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600267","BK0060","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662340751","title":"图解海正药业中报：第二季度单季净利润同比增长167.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662340751","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662340751?lang=zh_cn&edition=full","pubTime":"2026-08-26 02:20","pubTimestamp":1787682018,"startTime":"0","endTime":"0","summary":"证券之星消息，海正药业2026年中报显示，上半年度公司主营收入44.75亿元，同比下降14.76%；归母净利润6.36亿元，同比上升112.82%；扣非净利润5.13亿元，同比上升59.78%；其中2026年第二季度，公司单季度主营收入20.85亿元，同比下降20.37%；单季度归母净利润2.81亿元，同比上升167.81%；单季度扣非净利润2.77亿元，同比上升99.55%；负债率31.84%，投资收益1.76亿元，财务费用3133.85万元，毛利率55.58%。财报数据概要请见下图:本文数据来源于海正药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600005125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600267"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792317499590,"stockEarnings":[{"period":"1week","weight":-0.0821},{"period":"1month","weight":-0.0352},{"period":"3month","weight":-0.0318},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.0681},{"period":"ytd","weight":0.1308}],"compareEarnings":[{"period":"1week","weight":-0.0256},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0127},{"period":"6month","weight":-0.0827},{"period":"1year","weight":-0.0511},{"period":"ytd","weight":-0.0636}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海正药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"48826人(较上一季度增加2.42%)","perCapita":"24173股","listingDate":"2000-07-25","address":"浙江省台州市椒江区外沙路46号","registeredCapital":"118027万元","survey":" 浙江海正药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是海博麦布片（赛斯美）、注射用哌拉西林钠他唑巴坦钠（特治星）、盐酸米诺环素胶囊（玫满）、茚达特罗格隆溴铵吸入粉雾剂（杰润）、注射用丝裂霉素、瑞舒伐他汀钙片（海舒严）、注射用亚胺培南西司他丁钠（俊特）、米尔贝肟吡喹酮片（海乐妙）、丁二磺酸腺苷蛋氨酸肠溶片（喜美欣）、英夫马芬净。","listedPrice":11.83},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海正药业,600267,海正药业股票,海正药业股票老虎,海正药业股票老虎国际,海正药业行情,海正药业股票行情,海正药业股价,海正药业股市,海正药业股票价格,海正药业股票交易,海正药业股票购买,海正药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海正药业(600267)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海正药业(600267)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}